Comparison of 2-week versus 4-week dosing intervals of epoetin beta pegol on erythropoiesis and iron metabolism in hemodialysis patients.
Epoetin beta pegol (a continuous erythropoietin receptor activator; CERA) is usually administered once in 4 weeks or once monthly. However, the optimal dosing interval remains unknown. We, therefore, compared the effect of CERA administration between dosing intervals of 2 weeks (TWICE group) and 4 weeks (ONCE group) on erythropoiesis and iron metabolism in 20 hemodialysis patients. CERA was administered intravenously at weeks 0 and 2 for the TWICE group, and at week 0 for the ONCE group. Levels of hemoglobin (Hb), reticulocyte count, ferritin, transferrin saturation, content of Hb in reticulocytes and hepcidin-25 were monitored weekly for 4 weeks. Hemoglobin levels were significantly increased at weeks 3 and 4 in the TWICE group, while a gradual decrease after a significant increase at week 1 was observed in the ONCE group. Ferritin levels remained significantly low from week 1 to week 4 in the TWICE group. On the other hand, ferritin levels increased beyond baseline levels at week 4 in the ONCE group. Although hepcidin-25 did not significantly increase in the TWICE group, significant increases beyond baseline levels at weeks 3 and 4 were found in the ONCE group. These results indicate that continuous erythropoiesis was achieved with biweekly administration of CERA. Moreover, CERA at a 2-week interval led to a sustained suppression of ferritin and hepcidin-25 levels, suggesting a favorable influence on iron metabolism.
Blood Purification and Kidney Center, Konan Hospital, Kobe, Japan.
Yuki
Y
Morikami
Akira
A
Fujimori
Shioko
S
Okada
Mai
M
Kumei
Noriko
N
Mizobuchi
Makoto
M
Sakai
D000368:Aged; D000369:Aged, 80 and over; D004334:Drug Administration Schedule; D004920:Erythropoiesis / Q000187:drug effects*; D004921:Erythropoietin / Q000008:administration & dosage* / Q000494:pharmacology; D005260:Female; D005293:Ferritins / Q000378:metabolism; D006454:Hemoglobins / Q000378:metabolism; D064451:Hepcidins / Q000378:metabolism; D006801:Humans; D007501:Iron / Q000378:metabolism*; D008297:Male; D008875:Middle Aged; D011092:Polyethylene Glycols / Q000008:administration & dosage* / Q000494:pharmacology; D006435:Renal Dialysis; D012156:Reticulocytes / Q000378:metabolism
D006454:Hemoglobins; D064451:Hepcidins; C508420:continuous erythropoietin receptor activator; C545475:hepcidin 25, human; D004921:Erythropoietin; D011092:Polyethylene Glycols; D005293:Ferritins; D007501:Iron
Dialysis; Epoetin beta pegol; Ferritin; Hepcidin-25; Renal anemia